BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 1560703)

  • 1. [The 1990 drug law. Its implications for the clinical doctor].
    Castillo Pérez P; Gutiérrez López JF
    Med Clin (Barc); 1992 Feb; 98(7):263-9. PubMed ID: 1560703
    [No Abstract]   [Full Text] [Related]  

  • 2. International reporting on adverse drug reactions: the CIOMS project. CIOMS ADR Working Group.
    Faich GA; Castle W; Bankowski Z
    Int J Clin Pharmacol Ther Toxicol; 1990 Apr; 28(4):133-8. PubMed ID: 2338366
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The case for preemption of prescription drug failure-to-warn claims.
    Kim CH
    Food Drug Law J; 2007; 62(2):399-422. PubMed ID: 17632969
    [No Abstract]   [Full Text] [Related]  

  • 4. Recent developments in pharmaceutical products liability law: failure to warn, the learned intermediary defense, and other issues in the new millennium.
    Garbutt BJ; Hofmann ME
    Food Drug Law J; 2003; 58(2):269-86. PubMed ID: 12866558
    [No Abstract]   [Full Text] [Related]  

  • 5. [Drug monitoring].
    Royer RJ
    Bull Soc Ophtalmol Fr; 1985 Nov; Spec No():11-30. PubMed ID: 4064240
    [No Abstract]   [Full Text] [Related]  

  • 6. The federal preemption debate in pharmaceutical labeling product liability actions.
    Gross JM; Curry JA
    Tort Trial Insur Pract Law J; 2007; 43(1):35-70. PubMed ID: 18354866
    [No Abstract]   [Full Text] [Related]  

  • 7. [Mandatory report of adverse effects of drugs: has the order modified the spontaneous notification?].
    Haramburu F; Pere JC; Begaud B; Albin H
    Therapie; 1988; 43(6):493-6. PubMed ID: 3227516
    [No Abstract]   [Full Text] [Related]  

  • 8. Medicine goes Madison Avenue: an evaluation of the effect of direct-to-consumer pharmaceutical advertising on the learned intermediary doctrine.
    Allen MC
    Spec Law Dig Health Care Law; 1998 Dec; (236):9-29. PubMed ID: 10187553
    [No Abstract]   [Full Text] [Related]  

  • 9. [Drug regulation in Spain].
    Rubio Terrés C
    Med Clin (Barc); 1992 May; 98(19):741-8. PubMed ID: 1608280
    [No Abstract]   [Full Text] [Related]  

  • 10. [Comparative organization of drug monitoring in France and 7 European countries].
    Vaissere J; de Cremiers F; Auriche M; Juillet Y
    Therapie; 1986; 41(5):369-74. PubMed ID: 3810527
    [No Abstract]   [Full Text] [Related]  

  • 11. Current status of the drug safety monitoring system in Korea.
    Park BJ
    Pharmacoepidemiol Drug Saf; 2001; 10(6):557-60. PubMed ID: 11828840
    [No Abstract]   [Full Text] [Related]  

  • 12. [Detection of side effects. 2: Responsibilities of the pharmaceutical industry, drug commissions, the Federal Health Office and international organizations].
    Gleiter CH; Bieck PR
    Fortschr Med; 1991 Jul; 109(21):429-31. PubMed ID: 1916572
    [No Abstract]   [Full Text] [Related]  

  • 13. Pharmaceutical postmarket review: fact or fiction?
    Schanz SJ
    Food Drug Law J; 2007; 62(3):493-500. PubMed ID: 17915391
    [No Abstract]   [Full Text] [Related]  

  • 14. FDA attempting to overcome major roadblocks in monitoring drug safety.
    Zielinski SL
    J Natl Cancer Inst; 2005 Jun; 97(12):872-3. PubMed ID: 15956645
    [No Abstract]   [Full Text] [Related]  

  • 15. [4-year experience in drug surveillance].
    Capellà D; Avila P; Cabeza L; Moreno V; Vidal X; Laporte JR
    Med Clin (Barc); 1988 Jun; 91(3):93-6. PubMed ID: 3172912
    [No Abstract]   [Full Text] [Related]  

  • 16. [Minimal information that should be found in reports about suspected adverse reactions of drugs].
    Laporte JR; Lience E
    Med Clin (Barc); 1991 Jun; 97(2):56-7. PubMed ID: 1895784
    [No Abstract]   [Full Text] [Related]  

  • 17. [Drug surveillance and the safety of drugs: guidelines for legislative and total cultural action].
    Laporte JR
    Rev Med Univ Navarra; 1988; 32(1):31-3. PubMed ID: 3175437
    [No Abstract]   [Full Text] [Related]  

  • 18. [The new norms decreed by the legislative dirrective 91-93 CCE].
    Neri M; Palazzo S
    Boll Chim Farm; 1998 Feb; 137(2):31-4. PubMed ID: 9595832
    [TBL] [Abstract][Full Text] [Related]  

  • 19. European commission consultation on pharmacovigilance.
    Waller P; Beard K; Egberts T; Evans S; Hallas J; Hasford J; Laporte JR; Moore N; Shakir S; Sturkenboom M
    Pharmacoepidemiol Drug Saf; 2008 Feb; 17(2):108-9. PubMed ID: 18058839
    [No Abstract]   [Full Text] [Related]  

  • 20. [The Spanish drug surveillance system].
    Laporte JR; Capellà D
    Med Clin (Barc); 1994 Sep; 103(9):335-6. PubMed ID: 7967892
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.